MedPath

BIOCON LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

53

Active:0
Completed:35

Trial Phases

5 Phases

Phase 1:8
Phase 2:13
Phase 3:16
+2 more phases

Drug Approvals

16

SFDA:9
PHILIPPINES:5
NMPA:1
+1 more agencies

Drug Approvals

Pioglitazone Hydrochloride

Product Name
盐酸吡格列酮
Approval Number
H20170158
Approval Date
Mar 22, 2017
NMPA

Clinical Trials

Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials

Phase 3
16 (31.4%)
Phase 2
13 (25.5%)
Phase 4
9 (17.6%)
Phase 1
8 (15.7%)
Not Applicable
3 (5.9%)
phase_1_2
1 (2.0%)
phase_2_3
1 (2.0%)

Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
First Posted Date
2022-06-10
Last Posted Date
2023-05-09
Lead Sponsor
Biocon Limited
Target Recruit Count
78
Registration Number
NCT05413863
Locations
🇩🇪

Profil Institut für Stoffwechselforschung GmbH 9, Neuss, Germany

Efficacy and Safety of Itolizumab in COVID-19 Complications

Phase 2
Completed
Conditions
Acute Respiratory Distress Syndrome
Cytokine Release Syndrome
Covid19
Interventions
Drug: Best supportive care (BSC)
First Posted Date
2020-07-17
Last Posted Date
2021-06-14
Lead Sponsor
Biocon Limited
Target Recruit Count
32
Registration Number
NCT04475588
Locations
🇮🇳

Topiwala National Medical College & B. Y. L. Nair Charitable Hospital,, Mumbai, India

🇮🇳

Seth GS Medical College and KEM Hospital, Mumbai, India

🇮🇳

MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital, New Delhi, India

and more 1 locations

Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil

Phase 1
Terminated
Conditions
Type 1 Diabetes Mellitus (T1DM)
Interventions
Drug: Tregopil
First Posted Date
2019-10-28
Last Posted Date
2022-06-27
Lead Sponsor
Biocon Limited
Target Recruit Count
55
Registration Number
NCT04141423
Locations
🇩🇪

Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz, Germany

Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

Phase 1
Completed
Conditions
Healthy Volunteer
First Posted Date
2019-07-17
Last Posted Date
2020-01-30
Lead Sponsor
Biocon Limited
Target Recruit Count
78
Registration Number
NCT04022291
Locations
🇩🇪

Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz, Germany

🇩🇪

Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss, Neuss, Germany

Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N

Phase 1
Completed
Conditions
Healthy Volunteer
First Posted Date
2019-07-17
Last Posted Date
2020-01-30
Lead Sponsor
Biocon Limited
Target Recruit Count
90
Registration Number
NCT04022304
Locations
🇩🇪

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

  • Prev
  • 1
  • 2
  • Next

News

FDA Approves Kirsty as First Interchangeable Rapid-Acting Insulin Aspart Biosimilar

The FDA has approved Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar to NovoLog, expanding treatment options for diabetes patients.

Biocon Receives Indian Regulatory Approval for Generic Liraglutide, Expanding GLP-1 Diabetes Treatment Access

Biocon Limited has received approval from India's CDSCO for its generic version of Victoza (liraglutide), marking the company's first vertically integrated GLP-1 diabetes therapy clearance in the country.

Biocon Pharma Secures FDA Approval for Norepinephrine Bitartrate Injection for Acute Hypotension

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received FDA approval for Norepinephrine Bitartrate Injection USP, used to raise blood pressure in adults with acute hypotension.

Itolizumab Shows Promising Results in Phase 2 Ulcerative Colitis Trial, Matching Adalimumab Efficacy

Itolizumab demonstrated a 23.3% clinical remission rate in moderate to severe ulcerative colitis patients after 12 weeks, comparable to adalimumab's 20.0% and superior to placebo's 10.0%.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.